RADICAVA
Total Payments
$8.2M
Transactions
12,153
Doctors
3,848
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $406,329 | 3,339 | 1,796 |
| 2023 | $1.5M | 2,645 | 1,516 |
| 2022 | $243,489 | 2,791 | 1,559 |
| 2021 | $3.0M | 2,115 | 1,186 |
| 2020 | $3.0M | 934 | 616 |
| 2019 | $70,951 | 329 | 220 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.6M | 138 | 92.6% |
| Food and Beverage | $234,442 | 11,755 | 2.9% |
| Consulting Fee | $220,474 | 123 | 2.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $98,052 | 8 | 1.2% |
| Space rental or facility fees (teaching hospital only) | $18,750 | 8 | 0.2% |
| Travel and Lodging | $15,457 | 58 | 0.2% |
| Grant | $15,000 | 1 | 0.2% |
| Education | $1,576 | 62 | 0.0% |
Payments by Type
Research
$7.6M
138 transactions
General
$603,751
12,015 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| RADICAVA EDAVARONE FINDINGS IN BIOMARKERS FROM ALS REFINE-ALS | MITSUBISHI TANABE PHARMA AMERICA, INC. | $2.5M | 0 |
| RADICAVA (EDAVARONE) FINDINGS IN BIOMARKERS FROM ALS (REFINE-ALS) | Mitsubishi Tanabe Pharma America, Inc. | $2.3M | 0 |
| RADICAVA (EDAVARONE) FINDINGS IN BIOMARKERS FROM ALS (REFINE-ALS) | MITSUBISHI TANABE PHARMA AMERICA, INC. | $932,365 | 0 |
| REFINE-ALS (BIOMARKER STUDY) | MITSUBISHI TANABE PHARMA AMERICA, INC. | $518,152 | 0 |
| HOME-BASED SPIROMETRY THROUGH TELEMEDICINE IN AMYOTROPIC LATERAL SCLEROSIS | MITSUBISHI TANABE PHARMA AMERICA, INC. | $351,297 | 0 |
| ANALYSIS OF HUMAN ALS TISSUES AND REGISTRY OF ALS PATIENTS | MITSUBISHI TANABE PHARMA AMERICA, INC. | $178,596 | 0 |
| EFFECT OF MULTIDISCIPLINARY AND TRADITIONAL NON-MULTIDISCIPLINARY CARE PARADIGMS ON HEALTHCARE OUTCOMES, QUALITY OF LIFE AND COST | MITSUBISHI TANABE PHARMA AMERICA, INC. | $160,501 | 0 |
| Effect Of Multidisciplinary And Traditional Non-Multidisciplinary Care Paradigms On Healthcare Outcomes, Quality Of Life And Cost | MITSUBISHI TANABE PHARMA AMERICA, INC. | $160,501 | 0 |
| CHICAGO ALS BIOMARKER STUDY | MITSUBISHI TANABE PHARMA AMERICA, INC. | $138,908 | 0 |
| STUDY OF THE EFFECTS OF EDAVARONE ON TDP-43 DEPOSITION WITHIN DERMAL NERVES OF PATIENTS WITH ALS | MITSUBISHI TANABE PHARMA AMERICA, INC. | $124,594 | 0 |
| INVESTIGATOR INITIATED TRIAL (IIT) | MITSUBISHI TANABE PHARMA AMERICA, INC. | $102,063 | 0 |
| RADICAVA EDAVARONE FINDINGS IN BIOMARKERS FROM ALS REFINE-ALS | Mitsubishi Tanabe Pharma America, Inc. | $54,183 | 0 |
| REFINE-ALS STUDY (BIOMARKERS STUDY) | MITSUBISHI TANABE PHARMA AMERICA, INC. | $46,500 | 0 |
| HOME-BASED SPIROMETRY THROUGH TELEMEDICINE IN AMYOTROPHIC LATERAL SCLEROSIS | MITSUBISHI TANABE PHARMA AMERICA, INC. | $31,909 | 0 |
Top Doctors Receiving Payments for RADICAVA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Frank Thomas | — | Decatur, AL | $7.7M | 151 |
| , MD | Internal Medicine | Charlotte, NC | $34,459 | 18 |
| , MD | Clinical Neurophysiology | Fresno, CA | $24,094 | 23 |
| , M.D | Neurology | Los Angeles, CA | $16,458 | 13 |
| , M.D | Neurology | Lincoln, NE | $16,006 | 35 |
| , M.D | Neurology | Columbus, OH | $12,836 | 11 |
| , M.D | Neuromuscular Medicine | San Antonio, TX | $10,944 | 12 |
| , MD | Neurology | Jacksonville, FL | $10,714 | 12 |
| , M.D | Neurology | Houston, TX | $10,144 | 11 |
| , MD | Neurology | Minneapolis, MN | $9,075 | 10 |
| , M.D | Neurology | Phoenix, AZ | $9,070 | 6 |
| , M.D | Anatomic Pathology & Clinical Pathology | San Francisco, CA | $8,827 | 22 |
| , MD | Neurology | Los Angeles, CA | $8,702 | 15 |
| , MD | Neurology | Columbia, MO | $8,138 | 8 |
| , MD | Neurology | Philadelphia, PA | $6,676 | 9 |
| , MD | Neurology | Tampa, FL | $6,466 | 11 |
| , M.D | Neurology | Grand Rapids, MI | $6,452 | 4 |
| , M.D | Neurology | Amherst, NY | $6,263 | 27 |
| , MD | Clinical Neurophysiology | Saint Louis, MO | $6,050 | 6 |
| , M.D | Neuromuscular Medicine | Chattanooga, TN | $5,387 | 15 |
| , MD | Neurology | Orange, CA | $4,653 | 8 |
| , M.D | Neurology | Scottsdale, AZ | $4,599 | 7 |
| , M.D | Neurology | Orange, CA | $4,555 | 7 |
| , M.D. PH.D | Neurology | Durham, NC | $4,490 | 5 |
| Kourosh Rezania | Neurology | Burr Ridge, IL | $4,479 | 5 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $8.2M
- Total Doctors 3,848
- Transactions 12,153
About RADICAVA
RADICAVA is a drug associated with $8.2M in payments to 3,848 healthcare providers, recorded across 12,153 transactions in the CMS Open Payments database. The primary manufacturer is Mitsubishi Tanabe Pharma America, Inc..
Payment data is available from 2019 to 2024. In 2024, $406,329 was paid across 3,339 transactions to 1,796 doctors.
The most common payment nature for RADICAVA is "Unspecified" ($7.6M, 92.6% of total).
RADICAVA is associated with 14 research studies, including "RADICAVA EDAVARONE FINDINGS IN BIOMARKERS FROM ALS REFINE-ALS" ($2.5M).